Condition
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 3 (1)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06409663Phase 3CompletedPrimary
A Strain Change Study for SARS-CoV-2 rS Vaccines
NCT05693272Phase 1CompletedPrimary
A Clinical Trial to Study the COVAC-1 Booster Dose in Generally Healthy Adults
NCT06291883Phase 1Completed
Evaluation of KGR Prescriptions in Suppressing COVID-19 Infection.
NCT05458557CompletedPrimary
Antigen Rapid Diagnostic Tests for Community Identification of Severe Acute Respiratory Syndrome Coronavirus 2
Showing all 4 trials